127 related articles for article (PubMed ID: 17048434)
1. Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children.
Engchanil C; Kosalaraksa P; Lumbiganon P; Lulitanond V; Pongjunyakul P; Thuennadee R; Tungsawad S; Suwan-apichon O
J Med Assoc Thai; 2006 Aug; 89(8):1229-36. PubMed ID: 17048434
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
Gómez-Cano M; Soriano V; García-Lerma G; González-Lahoz J
An Med Interna; 1998 Mar; 15(3):145-7. PubMed ID: 9567422
[TBL] [Abstract][Full Text] [Related]
4. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
Gatell JM; Leal M; Mallolas J; Vidal C; Pumarola T; Parra R; Padró S; Caruz A; Falgueras T; Rey C; Sánchez-Quijano A; Torres Y; Lissen E; Jiménez de Anta MT; Soriano E
Antivir Ther; 1996 Apr; 1(2):105-12. PubMed ID: 11321180
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
[TBL] [Abstract][Full Text] [Related]
6. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
[TBL] [Abstract][Full Text] [Related]
7. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
8. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C
Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
[TBL] [Abstract][Full Text] [Related]
9. Review of viral load and combination therapy data from 35th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
Bray JM
STEP Perspect; 1995; 7(3):10-1. PubMed ID: 11362980
[TBL] [Abstract][Full Text] [Related]
10. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
Song R; Jelagat J; Dzombo D; Mwalimu M; Mandaliya K; Shikely K; Essajee S
Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
[TBL] [Abstract][Full Text] [Related]
12. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
13. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
Yerly S; Denereaz N; Mermillod B; Hirschel B; Perrin L
Antivir Ther; 1996 Aug; 1(3):167-71. PubMed ID: 11322250
[TBL] [Abstract][Full Text] [Related]
15. The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment.
Barroga CF; Raskino C; Fangon MC; Palumbo PE; Baker CJ; Englund JA; Spector SA
J Infect Dis; 2000 Aug; 182(2):413-9. PubMed ID: 10915070
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
[TBL] [Abstract][Full Text] [Related]
17. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.
Raskino C; Pearson DA; Baker CJ; Lifschitz MH; O'Donnell K; Mintz M; Nozyce M; Brouwers P; McKinney RE; Jimenez E; Englund JA
Pediatrics; 1999 Sep; 104(3):e32. PubMed ID: 10469815
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
Sangkitporn S; Shide L; Klinbuayaem V; Leenasirimakul P; Wirayutwatthana NA; Leechanachai P; Dettrairat S; Kunachiwa W; Thamlikitkul V
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):704-8. PubMed ID: 16124442
[TBL] [Abstract][Full Text] [Related]
19. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]